‚ª‚ñŽí•ʃVƒ…ƒxƒc@ƒŒƒWƒƒ“ˆê——ƒCƒ`ƒ‰ƒ“@
‚¨’TƒTƒK‚µ‚̃ŒƒWƒƒ“‚ðƒuƒ‰ƒEƒU‚ÌŒŸõƒPƒ“ƒTƒN‹@”\ƒLƒmƒE‚ÅŒŸõƒPƒ“ƒTƒN‚µ‚Ä‚­‚¾‚³‚¢B
‚ª‚ñ–¼ÌƒƒCƒVƒ‡ƒE‚ðƒNƒŠƒbƒN‚·‚邯ŠeƒJƒN‚ª‚ñŽíƒVƒ…ƒŒƒWƒƒ“‚ÌÚ׃Vƒ‡ƒEƒTƒCƒy[ƒW‚ɈÚsƒCƒRƒE‚µ‚Ü‚·B
ƒgƒbƒv‚ɖ߃‚ƒh‚é
MDS ƒŒƒWƒƒ“–¼ƒƒC
@ yS.C.zƒrƒ_[ƒU’P“ƃ^ƒ“ƒhƒNŽ¡—Ã`ƒŠƒ‡ƒE
‘½”­«ƒ^ƒnƒcƒZƒCœ‘ŽîƒRƒcƒYƒCƒVƒ… ƒŒƒWƒƒ“–¼ƒƒC
@ yS.C.zBDiƒxƒ‹ƒPƒCƒh”牺’ƒqƒJƒ`ƒ…ƒE+ƒfƒLƒTƒƒ^ƒ]ƒ“j
@ yS.C.zVRDа‰ð“±“üƒJƒ“ƒJƒCƒhƒEƒjƒ…ƒEƒxƒ‹ƒPƒCƒh”牺’ƒqƒJƒ`ƒ…ƒE{ƒŒƒuƒ‰ƒ~ƒh{ƒfƒLƒTƒƒ^ƒ]ƒ“
@ DLd(1ƒTƒCƒNƒ‹)
@ DLdi2ƒTƒCƒNƒ‹)
@ DLdi3`6ƒTƒCƒNƒ‹j
@ DLdi7ƒTƒCƒNƒ‹ˆÈ~)
@ Eld(1`2ƒTƒCƒNƒ‹)
@ Eldi3ƒTƒCƒNƒ‹ˆÈ~ƒCƒRƒEj
@ KRdi2`12ƒTƒCƒNƒ‹)
@ VMPа‰ð“±“üiƒxƒ‹ƒPƒCƒh”牺’j
@ VMPˆÛŽiƒxƒ‹ƒPƒCƒh”牺’j
@ KDi2ƒTƒCƒNƒ‹ˆÈ~)
@ PBD—Ö@i1`8ƒTƒCƒNƒ‹–Új
@ PBD—Ö@i9ƒTƒCƒNƒ‹–ÚˆÈ~j
@ weekly KD—Ö@i1ƒTƒCƒNƒ‹–Új
@ yƒVƒ‡[ƒgzweekly KD—Ö@i2ƒTƒCƒNƒ‹ˆÈ~j
@ EPDi1ƒTƒCƒNƒ‹j
@ EPDi2ƒTƒCƒNƒ‹j
@ EPDi3ƒTƒCƒNƒ‹j
@ EPDi4ƒTƒCƒNƒ‹ˆÈ~j
@ yS.C.2˜gzDBd—Ö@i1ƒTƒCƒNƒ‹–Új
@ yS.C.2˜gzDBd—Ö@i2`3ƒTƒCƒNƒ‹–Új
@ yS.C.2˜gzDBd—Ö@i4`8ƒTƒCƒNƒ‹–Új
@ yS.C.2˜gzDBd—Ö@i9ƒTƒCƒNƒ‹–ÚˆÈ~j
@ DCd—Ö@i2ƒTƒCƒNƒ‹–Új
@ DCd—Ö@i3`6ƒTƒCƒNƒ‹–Új
@ yS.C.2˜gzD-MPB—Ö@i2`9ƒTƒCƒNƒ‹–Új
@ yS.C.zDPd—Ö@i1ƒTƒCƒNƒ‹–Új
@ yS.C.zDPd—Ö@i2ƒTƒCƒNƒ‹–Új
@ yS.C.zDPd—Ö@i3-6ƒTƒCƒNƒ‹–Új
@ yS.C.zDPd—Ö@i7ƒTƒCƒNƒ‹–ÚˆÈ~j
@ y2˜gzIsaPd—Ö@i1ƒTƒCƒNƒ‹–Új
@ y2˜gzIsaPd—Ö@i2ƒTƒCƒNƒ‹–ÚˆÈ~j
”ñƒzƒWƒLƒ“ƒŠƒ“ƒpŽî ƒŒƒWƒƒ“–¼ƒƒC
@ y2˜gƒƒNzR-CHOP—Ö@ƒŠƒ‡ƒEƒzƒEi1“úƒjƒ`ŠÔƒJƒ“j
@ R+ƒxƒ“ƒ_ƒ€ƒXƒ`ƒ“i2“úŠÔƒjƒ`ƒJƒ“j
@ R
@ G-Bend
@ R+ƒxƒ“ƒ_ƒ€ƒXƒ`ƒ“—Ö@
@ G-Bend(1ƒTƒCƒNƒ‹)
@ G-Bend(‚QƒTƒCƒNƒ‹ˆÈ~)
@ ƒKƒUƒCƒo’P“ƈێ—Ö@
@ y2˜gzR-THP-COPi70-79Îj(1“úƒjƒ`ŠÔƒJƒ“j
@ y2˜gzR-THP-COPi80ΈÈãj(1“úŠÔj
@ R-CVPi1“úŠÔj
@ R-GCD
@ y2˜gzPola-BR—Ö@i2ƒTƒCƒNƒ‹–ÚˆÈ~j
@ y2˜gzPola-R-CHP—Ö@i2-6ƒTƒCƒNƒ‹–Új
@ yƒVƒ‡[ƒgzMTX-HOPE—Ö@
@ A-CHP
ƒzƒWƒLƒ“ƒŠƒ“ƒpŽîƒVƒ… ƒŒƒWƒƒ“–¼ƒƒC
@ ABVD
@ @
@ A-AVD
@ y¼®°ÄzƒLƒCƒgƒ‹[ƒ_
‹}«ƒLƒ…ƒEƒZƒCœ‘«ƒRƒcƒYƒCƒZƒC”’ŒŒ•aƒnƒbƒPƒcƒrƒ‡ƒE ƒŒƒWƒƒ“–¼ƒƒC
@ Ven{LDAC
@ Ven{AZA
”ñƒq¬×–EƒVƒ‡ƒEƒTƒCƒ{ƒE”xƒnƒC‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ y¼®°ÄzALM
@ yƒVƒ‡[ƒgznab-PTX’P“ƃ^ƒ“ƒhƒN
@ yƒVƒ‡[ƒgzNSCLC-Durvalmab
@ yƒVƒ‡[ƒgzNSCLC-Nivolumab
@ CBDCA+nab-PTX 1, 8, 15
@ Doc+Ram
@ non-sq: Pembro+CBDCA+ALM
@ NSCLC-Atezolizumab
@ NSCLC-Pembrolizumab
@ Sq: Pembro+CBDCA+nabPTC 
@ yƒVƒ‡[ƒgzAtezo+BevˆÛŽ—Ã–@
@ GEM+VNR@biweekly
@ NSCLC-Ipi-Nivo
@ yƒVƒ‡[ƒgzNSCLC-Nivolumab 4-week intervals
@ non-Sq: Pembro+ALMˆÛŽ—Ã–@
@ NSCLC-Pembrolizumab 6-week intervals
@ VNR1C8
@ y¼®°ÄzPEM
@ yƒVƒ‡[ƒgznab-PTX’P“ƃ^ƒ“ƒhƒN
@ yƒVƒ‡[ƒgzNSCLC-Durvalmab
@ yƒVƒ‡[ƒgzNSCLC-Nivolumab
@ CBDCA+nab-PTX 1, 8, 15
@ Doc+Ram
@ non-sq: Pembro+CBDCA+ALM
@ NSCLC-Atezolizumab
@ NSCLC-Pembrolizumab
@ Sq: Pembro+CBDCA+nabPAC 
@ yƒVƒ‡[ƒgzAtezo+BevˆÛŽ—Ã–@
@ GEM+VNR@biweekly
@ NSCLC-Ipi-Nivo
@ yƒVƒ‡[ƒgzNSCLC-Nivolumab 4-week intervals
@ non-Sq: Pembro+ALMˆÛŽ—Ã–@
@ NSCLC-Pembrolizumab 6-week intervals
@ VNR1C8
@ Sq: PembroˆÛŽ—Ã–@
@ y2˜gzCBDCA+PTX 1
@ CBDCA+PTX 1C8C15
@ DOC
@ y¼®°ÄzGEM@1C8
@ yƒVƒ‡[ƒgzBViƒAƒoƒXƒ`ƒ“’P“Æj
@ non-Sq@Pembro+CBDCA+PEM
@ non-Sq: Pembro+PEMˆÛŽ—Ã–@
@ y2˜gzAtezo+Bev+CBDCA+PAC
@ RAM+Erlotinib
@ y2˜gzAtezo+CBDCA+nab-PTX
@ CBDCA+TS-1
@ y¼®°ÄzƒeƒZƒ“ƒgƒŠƒNpŒã•╉»Šw—Ö@
¬×–EƒVƒ‡ƒEƒTƒCƒ{ƒE”xƒnƒC‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ y2˜gƒƒNzCDDP+CPT-11 1, 8, 15
@ y2˜gzCBDCA+ETP1C2C3
@ AMR@1C2C3
@ SCLC-AtezoˆÛŽ—Ã–@
@ CBDCA+ETP1C2C3
@ SCLC-durvalumab-CBDCA-ETP
@ NGT
@ SCLC-maintenance-Durvalumab
“ªèò•”ƒgƒEƒPƒCƒu‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ yƒVƒ‡[ƒgzƒIƒvƒW[ƒ{
@ ƒpƒNƒŠƒ^ƒLƒZƒ‹+ƒZƒcƒLƒVƒ}ƒu@‰‰ñ
@ ƒpƒNƒŠƒ^ƒLƒZƒ‹+ƒZƒcƒLƒVƒ}ƒui2‰ñ–ÚƒJƒCƒˆÈ~ƒCƒRƒEj
@ y¼®°Äzƒyƒ€ƒuƒƒŠƒYƒ}ƒu
@ ƒA[ƒrƒ^ƒbƒNƒX’P“Æi2ƒR[ƒX–ÚˆÈ~j
@ yƒVƒ‡[ƒgzƒIƒvƒW[ƒ{(4TŠÔŠÔŠuj
‘å’°ƒ_ƒCƒ`ƒ‡ƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ XELOXiƒ[ƒ[ƒ_+L-OHPj
@ ƒxƒNƒeƒBƒrƒbƒNƒXi6 mg/kgj+FOLFIRI
@ CPT-11+Pmab
@ FOLFIRI+ƒUƒ‹ƒgƒ‰ƒbƒv
@ FOLFIRI+ƒ‰ƒ€ƒVƒ‹ƒ}ƒu
@ FOLFOXIRI+Bev
@ UFT+LV+Bev
@ Weekly-Cetu+FOLFOX6iKRAS–ì¶Œ^j
@ ƒAƒoƒXƒ`ƒ“i10 mg/kgj+FOLFIRI
@ ƒAƒoƒXƒ`ƒ“i10 mg/kgj+mFOLFOX6
@ ƒAƒoƒXƒ`ƒ“i5 mg/kgj+FOLFIRI
@ ƒAƒoƒXƒ`ƒ“i7.5 mg/kgj+XELOX 
@ y2˜gzmFOLFOX6+Pmab
@ ƒA[ƒrƒ^ƒbƒNƒX’P“Æi2ƒR[ƒX–ÚˆÈ~j
@ mFOLFOX6
@ ƒAƒoƒXƒ`ƒ“ (5mg/kg) + mFOLFOX6
@ 5-FU+LV+BeviFOLFOXIRI+BevŒãˆÛŽ—Ã–@j
@ IRIS+ƒAƒoƒXƒ`ƒ“ (ƒAƒoƒXƒ`ƒ“+CPT11+TS-1 (SRIM ŽŽŒ±)
@ ƒxƒNƒeƒBƒrƒbƒNƒX@’P“Æ@i6mg/kgj
@ S-1+IRI+BEV ‚RTƒŒƒWƒƒ“
@ SOX + ƒAƒoƒXƒ`ƒ“ (TS-1 + L-OHP + ƒAƒoƒXƒ`ƒ“)
@ w-ƒA[ƒrƒ^ƒbƒNƒX + bi- CPT-11
@ y¼®°ÄzTAS102{BV
@ SOX  (TS-1 + L-OHP )
@ BEACON
@ ‘å’°Šà PER+HER 
@ ƒƒ“ƒT[ƒt+Bev
@ JACCRO CC-13FFOLFOXIRI+Bev
ˆÝƒC‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ iˆÝƒC‚ª‚ñ—pƒˆƒEjSOXiTS-1+L-OHPj
@ iˆÝƒC‚ª‚ñ—pƒˆƒEjXELOXiƒ[ƒ[ƒ_+L-OHP)
@ yƒVƒ‡[ƒgzGC-Nivolumab
@ CPT-11 ’P“ƃ^ƒ“ƒhƒN
@ SP+HERishort hydrationj
@ TS-1 + Docetaxel—Ö@
@ weekly PTX+ƒ‰ƒ€ƒVƒ‹ƒ}ƒu
@ (ˆÝ‚ª‚ñ—pjmFOLFOX6
@ y¼®°ÄzGC-Nivolumab (4w)
@ nab-PTX+RAM
@  FOLFOX{Nivo
@ SOX+HER
@ SOX{Nivo
@ weekly-PTX
@ XELOX{Nivo
H“¹ƒVƒ‡ƒNƒhƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ iH“¹ƒVƒ‡ƒNƒhƒE‚ª‚ñjweekly PTX
@ 3-weekly TXT
@ H“¹‚ª‚ñ-Nivolumab
@ H“¹‚ª‚ñ-Nivolumab (4w)
@ FP{Nivo(2T–ˆ)
@ y2˜gzFP{Pembro (6ƒR[ƒX‚Ü‚Å)
@ y¼®°ÄzH“¹Šà]Nivolumabi2wjipŒã•â•j
@ y¼®°ÄzH“¹Šà]Nivolumabi4wjipŒã•â•j
@ IPI{Nivo(2T–ˆ)
@ IPI{Nivo(3T–ˆ)
@ @ @ @
äX‘ŸƒXƒCƒ]ƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ y¼®°ÄzGEM’P“Æ (Ž¡—×p)
@ FOFIRINOX
@ nab-PTX+GEM
@ y2˜gzNal-IRI+5-FU/LV
@ GEM’P“Æ (Ž¡—×p)
@ GEM 1, 8 + TS-1 (2“Š1‹x)@(Ž¡—×p)
@ @ @ @
’_“¹ƒ^ƒ“ƒhƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ y2˜gƒƒNzGEM‡@‡G+CDDP‡@‡G
@ GCS—Ö@
@ y2˜gzDurvalumab+GEM+CDDP—Ö@
@ @
ŠÌ‘ŸƒJƒ“ƒ]ƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ ƒ‰ƒ€ƒVƒ‹ƒ}ƒu’P܃^ƒ“ƒUƒC
@ Atezo+Bmab
“ûƒjƒ…ƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ 3wk HER
@ GEM@1C8
@ CMFyp.o.ziCPA+MTX+5-FUj
@ DOC100
@ Doc75+PER+HER
@ EC80iEPI+CPAj
@ FEC100i5-FU+EPI+CPAj
@ PTX+PER{HER 
@ TC—Ö@ƒŠƒ‡ƒEƒzƒEyivziTXT+CPAyivzj
@ wPTX (12wk)
@ wPTX+ƒxƒoƒVƒYƒ}ƒu
@ ƒGƒŠƒuƒŠƒ“
@ ´ØÌÞØÝ+PER+HER
@ ƒJƒhƒTƒCƒ‰
@ y¼®°Äz2w VNR
@ ƒGƒ“ƒn[ƒc
@ GEM+PER{HER (2ƒR[ƒX–ÚˆÈ~)
@ Pembro{CG
@ Pembro{EC (NAC2)
@ Pembro{wPTX{wCBDCA (NAC1)
@ VNR 1C8
@ y¼®°Äz3wABX (ƒAƒuƒ‰ƒLƒTƒ“)
@ XT —Ö@ (DOC60+Xeloda)
@ GEM+CBDCA
@ ´ØÌÞØÝ+PER+HER(‚QƒR[ƒX–ÚˆÈ~)
@ VNR+PER{HER (2ƒR[ƒX–ÚˆÈ~)
”]ŽîᇃmƒEƒVƒ…ƒˆƒE ƒŒƒWƒƒ“–¼ƒƒC
@ yƒVƒ‡[ƒgzƒAƒoƒXƒ`ƒ“’P“ƃ^ƒ“ƒhƒN
tƒWƒ“‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ yƒVƒ‡[ƒgzƒeƒ€ƒVƒƒŠƒ€ƒX—Ö@ƒŠƒ‡ƒEƒzƒE
@ yƒVƒ‡[ƒgzƒjƒ{ƒ‹ƒ}ƒu—Ö@ƒŠƒ‡ƒEƒzƒEitƒWƒ“‚ª‚ñj
@ tŠàƒWƒ“ƒKƒ“ƒjƒ{ƒ‹ƒ}ƒu+ƒCƒsƒŠƒ€ƒ}ƒu@ʼnƒTƒCƒVƒ‡4ƒR[ƒX
@ ƒAƒxƒ‹ƒ}ƒu{ƒAƒLƒVƒ`ƒjƒu•¹—p—Ö@
@ ÆÎÞÙÏÌޗÖ@ 4TŠÔ»²¸ÙitŠà 2nd linej
@ tŠà ÍßÑÌÞÛØ½ÏÌÞ6TŠÔ{±·¼ÁÆÌÞ•¹—p—Ö@
@ ²ËßEÆÎÞŒã ÆÎÞÙÏÌÞ’PޗÖ@ 4w»²¸ÙitŠà j
@ y¼®°Äzƒjƒ{ƒ‹ƒ}ƒu{ƒJƒ{ƒUƒ“ƒ`ƒjƒu•¹—p—Ö@
@ y¼®°Äzƒjƒ{ƒ‹ƒ}ƒu4TŠÔ{ƒJƒ{ƒUƒ“ƒ`ƒjƒu•¹—p—Ö@
@ y¼®°Äzt×–EŠà ÍßÝÌÞÛØ½ÞÏÌÞ3T{ÚÝÊÞÁÆÌÞ•¹—p—Ö@
@ y¼®°Äzt×–EŠà ÍßÝÌÞÛØ½ÞÏÌÞ6T{ÚÝÊÞÁÆÌÞ•¹—p—Ö@
äNã÷ƒ{ƒEƒRƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ GEM+CBDCA—Ö@
@ UC-Pembrolizumab
@ ”A˜Hã”çŠà ÍßÑÌÞÛØ½ÏÌޗÖ@ 6TŠÔ»²¸Ù
@ ”A˜Hã”çŠà ƒpƒhƒZƒu—Ö@
@ ”A˜Hã”çŠà ƒAƒxƒ‹ƒ}ƒuˆÛŽ—Ã–@
@ (‰ü’ù”Å)GC
@ GEM+CBDCA—Ö@(30<CCr<60 CDDP•s‰ÂÇ—áj
@ y¼®°ÄzUCpŒãƒjƒ{ƒ‹ƒ}ƒu—Ö@ 2TŠÔƒTƒCƒNƒ‹
@ y¼®°ÄzUCpŒãƒjƒ{ƒ‹ƒ}ƒu—Ö@ 4TŠÔƒTƒCƒNƒ‹
‘O—§‘Bƒ[ƒ“ƒŠƒcƒZƒ“‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ Cabazitaxel—Ö@ƒŠƒ‡ƒEƒzƒE
@ Triweekly DOC
ˆ««ƒAƒNƒZƒC•FŽîƒRƒNƒVƒ‡ƒNƒVƒ… ƒŒƒWƒƒ“–¼ƒƒC
@ yƒVƒ‡[ƒgzMM biwekly Nivolumab
@ MM Nivolumab adjuvant 4W
@ MM@Pembrolizumab
@ MM Nivolumab 4W
@ Nivolumab+Ipilimumab
@ yƒVƒ‡[ƒgzMM-ƒyƒ“ƒuƒƒŠƒYƒ}ƒu@400‡r
@ y¼®°ÄzMM Nivolumab 4W
—‘‘ƒƒ‰ƒ“ƒ\ƒE‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ y2˜gƒƒNzPTX+CBDCA
@ y2˜gƒƒNzPTX+CBDCA+Bev
@ yƒVƒ‡[ƒgzGEM’P“ƃ^ƒ“ƒhƒN‡@‡G‡N
@ DOC+CBDCA
@ PLD+Bev
@ CPT-11+CDDP
@ PLD+CBDCA
@ dd-PTX ‡@ ‡G ‡N + CBDCA ‡@
@ BEP—Ö@
@ BevÒÝÃÅݽ
@ weeklyPTX+Bev
@ DOC+CBDCA+Bev
@ NGT
Žq‹{‘̃VƒLƒ…ƒEƒ^ƒC‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ AP—Ö@ƒŠƒ‡ƒEƒzƒE
@ PTX+CBDCA
@ y¼®°ÄzƒŒƒ“ƒrƒ}+ƒLƒCƒgƒ‹[ƒ_(200mg q3w)
@ DP—Ö@
Žq‹{ƒVƒLƒ…ƒEèòƒPƒC‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ y2˜gz‚b‚o‚s|11+‚m‚c‚o
@ TC-Bev
@ CPT-11’P“Æ ‡@ ‡G ‡N
@ y2˜gzPem+TCBev
@ Pem+BevˆÛŽ—Ã–@
ŒÅŒ`ƒRƒPƒC‚ª‚ñ ƒŒƒWƒƒ“–¼ƒƒC
@ MSI-High@pembro
@ y¼®°ÄzTMB-High 3T Pembro
ƒAƒ~ƒƒCƒh[ƒVƒX ƒŒƒWƒƒ“–¼ƒƒC
@ yS.CzDCyBorD—Ö@i1ƒTƒCƒNƒ‹–Új
@ yS.CzDCyBorD—Ö@i2ƒTƒCƒNƒ‹–Új
@ yS.CzDCyBorD—Ö@i3-6ƒTƒCƒNƒ‹–Új
@ yS.CzDCyBorD—Ö@i7ƒTƒCƒNƒ‹–ÚˆÈ~j
‹}«ƒLƒ…ƒEƒZƒCTƒŠƒ“ƒp«ƒZƒC”’ŒŒ•aƒnƒbƒPƒcƒrƒ‡ƒE ƒŒƒWƒƒ“–¼ƒƒC
@ ƒ|ƒeƒŠƒWƒI’P“ƃ^ƒ“ƒhƒN
“÷ŽîƒjƒNƒVƒ… ƒŒƒWƒƒ“–¼ƒƒC
@ y¼®°ÄzƒGƒŠƒuƒŠƒ“
@ DXR
Œ´”­•s–¾ŠàƒQƒ“ƒpƒcƒtƒƒCƒKƒ“ ƒŒƒWƒƒ“–¼ƒƒC
@ y¼®°ÄzNivo@CUP@240mg q2w